Solid Biosciences LLC (SLDB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Solid Biosciences LLC (SLDB) has a cash flow conversion efficiency ratio of -0.141x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.59 Million) by net assets ($374.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Solid Biosciences LLC (SLDB) market capitalisation for the company's overall valuation and market capitalisation.
Solid Biosciences LLC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Solid Biosciences LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Solid Biosciences LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solid Biosciences LLC ranked by their cash flow conversion efficiency. See Solid Biosciences LLC debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Intco Recycling Resources Co Ltd
SHG:688087
|
0.064x |
|
Uniphar Group PLC
IR:UPR
|
-0.017x |
|
Daxin Materials Corp
TW:5234
|
0.068x |
|
Xinke Material
SHG:600255
|
-0.100x |
|
CTT Correios de Portugal SA
LS:CTT
|
0.199x |
|
Hunan New Wellful Co Ltd
SHG:600975
|
0.064x |
|
HJ ShipBuilding & Construction Co Ltd
KO:097230
|
0.112x |
|
EST Tools Co Ltd
SHE:300488
|
0.012x |
Annual Cash Flow Conversion Efficiency for Solid Biosciences LLC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Solid Biosciences LLC from 2015 to 2025. View SLDB stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $180.01 Million | $-156.29 Million | -0.868x | -19.15% |
| 2024-12-31 | $137.25 Million | $-100.01 Million | -0.729x | +2.14% |
| 2023-12-31 | $126.48 Million | $-94.18 Million | -0.745x | -60.86% |
| 2022-12-31 | $211.67 Million | $-97.98 Million | -0.463x | -23.94% |
| 2021-12-31 | $208.21 Million | $-77.76 Million | -0.373x | +12.84% |
| 2020-12-31 | $132.09 Million | $-56.60 Million | -0.429x | +63.00% |
| 2019-12-31 | $80.05 Million | $-92.71 Million | -1.158x | -106.55% |
| 2018-12-31 | $125.18 Million | $-70.20 Million | -0.561x | -176.88% |
| 2017-12-31 | $-59.26 Million | $-43.22 Million | 0.729x | +37.35% |
| 2016-12-31 | $-37.89 Million | $-20.12 Million | 0.531x | +151.70% |
| 2015-12-31 | $-19.93 Million | $-4.20 Million | 0.211x | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more